Insider · CIK 0001681098
Neil F. McFarlane
Files at ZVRA (ZEVRA THERAPEUTICS, INC.). First filing Oct 10, 2025, latest Feb 10, 2026.
In brief
Neil F. McFarlane files SEC Form 4 as CEO, president and director at ZVRA (ZEVRA THERAPEUTICS, INC.). Since Oct 10, 2025, Neil F. McFarlane has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.2M, the latest filed on Feb 10, 2026.
A track record needs three past buys with six months of prices behind them; Neil F. McFarlane has 0, so none is measured yet.
The newest scored trade: sold $125k of ZVRA on Feb 9, 2026, filed Feb 10, 2026, scored 16 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $979k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZVRA: ZEVRA THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | ZEVRA THERAPEUTICS, INC. | $125k 14,625 shares | -4% | +31% from low-33% from high | |
| 33Weak | ZEVRA THERAPEUTICS, INC. | $853k 91,000 shares | -20% | +43% from low-27% from high | |
| 12Weak | ZEVRA THERAPEUTICS, INC. | $211k 19,500 shares | -8% | +68% from low-14% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 2, 2026 | ZVRA ZEVRA THERAPEUTICS INC | 105,625 0.19% of outstanding | $951k | Feb 2, 2026 | none |
| Oct 10, 2025 | ZVRA ZEVRA THERAPEUTICS INC | 19,500 0.03% of outstanding | $211k | Oct 10, 2025 | none |
| Feb 13, 2025 | ZVRA ZEVRA THERAPEUTICS INC | 91,817 0.17% of outstanding | $709k | Feb 13, 2025 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 7, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock10b5-1 | +37,500 | - | - | 401,850 | Feb 10, 2026 |
| Feb 9, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -14,625 | $8.56 | $125k | 387,225 | Feb 10, 2026 |
| Feb 7, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative10b5-1 | -37,500 | $0.00 | $0 | 75,000 | Feb 10, 2026 |
| Jan 31, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock10b5-1 | +233,334 | - | - | 455,350 | Feb 2, 2026 |
| Feb 2, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -91,000 | $9.38 | $853k | 364,350 | Feb 2, 2026 |
| Jan 29, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Restricted Stock Unitderivative10b5-1 | +125,000 | $0.00 | $0 | 125,000 | Feb 2, 2026 |
| Jan 29, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative10b5-1 | +250,000 | $0.00 | $0 | 250,000 | Feb 2, 2026 |
| Jan 31, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative10b5-1 | -233,334 | $0.00 | $0 | 233,333 | Feb 2, 2026 |
| Oct 10, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock10b5-1 | +50,000 | - | - | 241,516 | Oct 10, 2025 |
| Oct 10, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -19,500 | $10.82 | $211k | 222,016 | Oct 10, 2025 |
| Oct 10, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative10b5-1 | -50,000 | $0.00 | $0 | 100,000 | Oct 10, 2025 |
Questions about Neil F. McFarlane
Answered from the filings on this page, as of the latest one.
Is Neil F. McFarlane buying or selling?
In the last 12 months Neil F. McFarlane reported 0 open-market buys worth $0 and 2 open-market sells worth $979k on SEC Form 4; the latest was sold $125k of ZVRA on Feb 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Neil F. McFarlane's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Neil F. McFarlane has 0.
Where does Neil F. McFarlane file Form 4?
Neil F. McFarlane has filed Form 4 at ZVRA (ZEVRA THERAPEUTICS, INC.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.